Veloxis Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Horsholm Denmark (2002)
Status: Acquired by Asahi Kasei Pharma (2019)

Organization Overview

First Clinical Trial
2007
NCT00504829
First Marketed Drug
2015
tacrolimus (prograf)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Veloxis Pharmaceuticals | VELOXIS PHARMS INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Dyslipidemias (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Autoimmune (Phase 2)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Liver Failure (Phase 2)

Neurotoxicity Syndromes (Phase 4)

Renal Insufficiency (Phase 4)

Tremor (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial APIs: 13